MX2024009163A - Sintesis de un inhibidor de kif18a. - Google Patents
Sintesis de un inhibidor de kif18a.Info
- Publication number
- MX2024009163A MX2024009163A MX2024009163A MX2024009163A MX2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- kif18a
- inhibitor
- synthesis
- salt
- Prior art date
Links
- 101001091231 Homo sapiens Kinesin-like protein KIF18A Proteins 0.000 title abstract 2
- 229940126262 KIF18A Drugs 0.000 title abstract 2
- 102100034895 Kinesin-like protein KIF18A Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303470P | 2022-01-26 | 2022-01-26 | |
| PCT/US2023/011636 WO2023146973A1 (en) | 2022-01-26 | 2023-01-26 | Synthesis of a kif18a inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009163A true MX2024009163A (es) | 2024-08-09 |
Family
ID=85328813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009163A MX2024009163A (es) | 2022-01-26 | 2023-01-26 | Sintesis de un inhibidor de kif18a. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250129050A1 (enExample) |
| EP (1) | EP4469437A1 (enExample) |
| JP (1) | JP2025505892A (enExample) |
| KR (1) | KR20240144140A (enExample) |
| CN (1) | CN118922406A (enExample) |
| AR (1) | AR128353A1 (enExample) |
| AU (1) | AU2023211589A1 (enExample) |
| CA (1) | CA3248925A1 (enExample) |
| IL (1) | IL314221A (enExample) |
| MX (1) | MX2024009163A (enExample) |
| TW (1) | TW202342451A (enExample) |
| WO (1) | WO2023146973A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| WO2024039829A1 (en) | 2022-08-18 | 2024-02-22 | Accent Therapeutics, Inc. | Inhibitors of kif18a and uses thereof |
| CN115925589A (zh) * | 2022-12-26 | 2023-04-07 | 诚达药业股份有限公司 | 一种脂肪族亚磺酸钙盐及其制备方法 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211475A1 (es) * | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| TW202203919A (zh) * | 2020-04-14 | 2022-02-01 | 美商安進公司 | 用於治療贅生性疾病之kif18a抑制劑 |
-
2023
- 2023-01-26 CA CA3248925A patent/CA3248925A1/en active Pending
- 2023-01-26 IL IL314221A patent/IL314221A/en unknown
- 2023-01-26 KR KR1020247024721A patent/KR20240144140A/ko active Pending
- 2023-01-26 US US18/832,887 patent/US20250129050A1/en active Pending
- 2023-01-26 AU AU2023211589A patent/AU2023211589A1/en active Pending
- 2023-01-26 CN CN202380018655.9A patent/CN118922406A/zh active Pending
- 2023-01-26 WO PCT/US2023/011636 patent/WO2023146973A1/en not_active Ceased
- 2023-01-26 JP JP2024543870A patent/JP2025505892A/ja active Pending
- 2023-01-26 EP EP23706921.6A patent/EP4469437A1/en active Pending
- 2023-01-26 AR ARP230100178A patent/AR128353A1/es unknown
- 2023-01-26 MX MX2024009163A patent/MX2024009163A/es unknown
- 2023-01-30 TW TW112103047A patent/TW202342451A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR128353A1 (es) | 2024-04-24 |
| CN118922406A (zh) | 2024-11-08 |
| CA3248925A1 (en) | 2023-08-03 |
| KR20240144140A (ko) | 2024-10-02 |
| AU2023211589A1 (en) | 2024-07-25 |
| WO2023146973A1 (en) | 2023-08-03 |
| EP4469437A1 (en) | 2024-12-04 |
| IL314221A (en) | 2024-09-01 |
| US20250129050A1 (en) | 2025-04-24 |
| JP2025505892A (ja) | 2025-03-03 |
| TW202342451A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128353A1 (es) | Síntesis de un inhibidor de kif18a | |
| AR117101A1 (es) | Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras | |
| CO2023014807A2 (es) | Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras | |
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| CL2024003354A1 (es) | Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras | |
| CL2021000737A1 (es) | Fabricación de compuestos y composiciones para inhibir la actividad de shp2 | |
| CO6400227A2 (es) | Análogos de nucleosidos | |
| CL2020001871A1 (es) | Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco. | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| DOP2025000087A (es) | Compuestos tricíclicos y sus usos | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| AR069798A1 (es) | Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa. | |
| CY1114689T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
| MXPA04002993A (es) | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios. | |
| MX2024012348A (es) | Forma cristalina de lanifibranor | |
| AR124694A1 (es) | Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo | |
| CO2024013702A2 (es) | Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3 | |
| CL2021002575A1 (es) | Compuestos de pirrol | |
| EA201290872A1 (ru) | Способ получения бензоксаборолов | |
| CL2021000171A1 (es) | Procedimiento y productos intermedios para la preparación de bilastina | |
| UY39789A (es) | Intermedio novedoso para la preparación de piroxasulfona. | |
| PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
| PA8650401A1 (es) | Sintesis asimetrica de dihidrobenzofuranos sustituidos |